SSRIs: Applications in inflammatory lung disease and implications for COVID‐19
Abstract Selective serotonin reuptake inhibitors (SSRIs) have anti‐inflammatory properties that may have clinical utility in treating severe pulmonary manifestations of COVID‐19. SSRIs exert anti‐inflammatory effects at three mechanistic levels: (a) inhibition of proinflammatory transcription factor...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-09-01
|
| Series: | Neuropsychopharmacology Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/npr2.12194 |